The backtest results show that ABVX experienced poor short-term performance following earnings beats, with 0% win rates at 3 and 10 days and negative returns of -12.07% and -21.09%, respectively. However, the 30-day win rate improves to 50%, and the cumulative return approaches breakeven at -1.23%, indicating some recovery over a longer horizon. This suggests that immediate market reactions to ABVX earnings beats tend to be negative, but the stock may stabilize or recover over a month. Investors should be cautious about short-term trades post-earnings beat and consider longer holding periods for potential gains.

backtest_data

The backtest results for ABVX following earnings misses show a consistent 50% win rate across 3, 10, and 30 days, with a notable 22.72% average return over 30 days. The maximum return reached 74.04% by day 33, indicating significant upside potential despite the initial negative event. This suggests that ABVX may experience volatile but potentially rewarding price movements after earnings disappointments.

The results imply that while short-term outcomes are uncertain, longer-term gains are possible, highlighting the importance of holding through volatility.

Investors might consider a strategic position in ABVX post-earnings miss to capitalize on potential rebounds.

The backtest results show that the Biotechnology Industry experienced a slight negative impact following earnings beats, with a maximum return of only 0.29% observed 15 days after the event. This minimal positive return suggests that earnings beats in this sector do not strongly translate into significant stock price gains. Consequently, the data implies that investors should be cautious about expecting substantial upside from earnings beats in the Biotechnology Industry and consider other factors when making investment decisions in this sector.

The backtest results show that earnings misses in the Biotechnology Industry had no significant impact, with a maximum return of -0.08% observed three days after the event. This negligible effect suggests that the market does not strongly react to earnings misses within this sector over the tested period.

The analysis indicates that investors may not need to adjust their positions based solely on earnings misses in Biotechnology stocks, as these events do not materially influence returns.

Therefore, investment strategies should consider other factors beyond earnings misses when evaluating Biotechnology industry stocks.

Backtest ABVX Release Earning Report

Find all upcoming company earnings reports scheduled for dec 14 2026. Get details on which companies are reporting and their expected results.

Calendario